Unlimited Email and Phone number
Everything you need to reach more inboxes and close more deals
Unlimited Contact Only at$79
Michael Kranda
Board Member, Chief Business Officer @Aclipse Therapeutics
Signup · Get unlimited contacts
WORK HISTORY
Board Member, Chief Business Officer @Aclipse Therapeutics
King of Prussia, PA, US
Aclipse Therapeutics is a clinical stage company focused on molecular pathways that regulate cellular stress, protein misfolding and inflammation. We are currently developing two in-licensed clinical assets with 7 potential indications and existing $30 billion markets. M107 is primed to enter a Ph2 trial for the treatment of gastroparesis. M107 has the potential to modify the disease by restoring normal gastric pacemaker function.M102 is primed to enter a Ph 1 trial next year for the treatment of sporadic ALS and designed to activate both Nrf2 and HSF1 pathways. Further, we are developing biomarkers based on patient PBMCs to identify potential drug responders and exploring Parkinson’s and Friedreich’s Ataxia as potential additional indications.
EDUCATION
University of Washington
MBA, Finance
SKILLS
ABOUT MICHAEL KRANDA
Background | Board & Product to Market Details | Skills | Patents Served in…
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.